Colorectal Cancer Clinical Trial
— ICG-COLORALOfficial title:
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
This is a randomized, controlled, parallel, multicenter trial to determine the difference in post-operative anastomotic leakages in colorectal surgery, where anastomosis perfusion is evaluated using indocyanine green fluorescence imaging as an addition to standard surgical practice compared to surgical practice alone.
Status | Recruiting |
Enrollment | 1062 |
Est. completion date | December 1, 2023 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All consenting patients in the catchment area of participating hospitals who undergo elective colorectal surgery with planned primary anastomosis are eligible for this study. - Of rectal cancer patients only those with pathology in the proximal third will be included in the study (defined by area proximal from peritoneal fold). Exclusion Criteria: - Emergent patients - Patients with proven diverticular abscess and colonic fistulas are excluded - Patients with planned open surgery are excluded. |
Country | Name | City | State |
---|---|---|---|
Finland | Central Finland Central Hospital | Jyväskylä | |
Finland | Päijät Häme Central Hospital | Lahti |
Lead Sponsor | Collaborator |
---|---|
Oulu University Hospital | Central Finland Hospital District, Hospital District of Helsinki and Uusimaa, Päijänne Tavastia Central Hospital, Seinäjoki Central Hospital, Seinäjoki, Finland, Tampere University Hospital, Turku University Hospital, University of Oulu |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anastomosis leakage rate | 0 to 90 days | ||
Secondary | Severity of anastomosis leakage | Grade A-C according to International Study Group of Rectal Cancer | 0 to 90 days | |
Secondary | Timing of anastomosis leakage | Days | 0 to 90 days | |
Secondary | Deep surgical site infections | Yes/no | 0 to 90 days | |
Secondary | Hospital readmission rate | 0 to 90 days | ||
Secondary | Reoperation rate | 0 to 90 days | ||
Secondary | 30- and 90-day complications according to Clavien-Dindo Classification | Clavien-Dindo Score from Grade 0 (no complications) to Grade V (Death of a patient). Five grades and additionally Grade III and IV will be divided to a and b. | 0 to 90 days | |
Secondary | Operation time | Time from the start of the operation until the surgeon has ended the operation | 0-600 minutes | |
Secondary | Length of hospital stay | Day of the operation is considered the day 0 | 0-365 days | |
Secondary | 30- and 90-day mortality | 0 to 90 days | ||
Secondary | Time to first bowel movement | Postoperative day when the first bowel movement occurs | 0-30 days | |
Secondary | Time to first flatus | Postoperative day when the first flatus occurs | 0-30 days | |
Secondary | Hospital costs | 0 to 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |